Cargando…

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study

Detalles Bibliográficos
Autores principales:	Ciresi, Alessandro, Vigneri, Enrica, Radellini, Stefano, Pantò, Felicia, Giordano, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984926/ https://www.ncbi.nlm.nih.gov/pubmed/29637460 http://dx.doi.org/10.1007/s13300-018-0423-3

Ejemplares similares

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2017)

One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

Author Correction: Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
por: Zhao, Miao-Miao, et al.
Publicado: (2021)

Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras
por: Guarnotta, Valentina, et al.
Publicado: (2021)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
por: Lund, Søren S, et al.
Publicado: (2009)

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis
por: Guarnotta, Valentina, et al.
Publicado: (2018)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

The metabolic outcomes of growth hormone treatment in children are gender specific
por: Ciresi, Alessandro, et al.
Publicado: (2018)

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study
por: Guarnotta, V., et al.
Publicado: (2020)

Hypolipidaemic and Insulin Secretagogue Activities of (R)-(−)-Carvone
por: Abbas, Manal Ahmad, et al.
Publicado: (2020)

Contribution of Mitochondria to Insulin Secretion by Various Secretagogues
por: Ježek, Petr, et al.
Publicado: (2022)

Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
por: Chen, Jianhua, et al.
Publicado: (2023)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Antihyperglycemic and Insulin Secretagogue Activities of Abrus precatorius Leaf Extract
por: Umamahesh, Balekari, et al.
Publicado: (2016)

Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
por: Zhao, Miao-Miao, et al.
Publicado: (2021)

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control
por: Ciresi, Alessandro, et al.
Publicado: (2018)

ASO Author Reflections: Magnetic Seed Localization and Tracers Add Value to Multidisciplinary Breast Programs
por: Miller, Megan E., et al.
Publicado: (2020)

Efficacy and safety of photodynamic therapy with RLP068 for diabetic foot ulcers: a review of the literature and clinical experience
por: Pantò, Felicia, et al.
Publicado: (2020)

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (BEGIN: ADD TO GLP‐1 Study)
por: Aroda, V. R., et al.
Publicado: (2016)

Circulating adipokines data associated with insulin secretagogue use in breast cancer patients
por: Wintrob, Zachary A.P., et al.
Publicado: (2016)

A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent
por: Sugawara, Kenji, et al.
Publicado: (2016)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
por: DeWaal, Dannielle, et al.
Publicado: (2018)

Author Correction: Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells
por: Alhourani, Abdelnour H., et al.
Publicado: (2022)

Author Correction: Green synthesis and characterization of silver nanoparticles for reducing the damage to sperm parameters in diabetic compared to metformin
por: Ali, Iman A. Mohammed, et al.
Publicado: (2023)

Author Correction: Molecular engineering of safe and efficacious oral basal insulin
por: Hubálek, Frantisek, et al.
Publicado: (2020)

Correction: A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agent
Publicado: (2017)

Association Between Serious Hypoglycemia and Calcium-Channel Blockers Used Concomitantly With Insulin Secretagogues
por: Nam, Young Hee, et al.
Publicado: (2021)

Interprofessional Continuous Glucose Monitoring for Underserved Adults with Type 2 Diabetes on Insulin or Secretagogues
por: Fasina, Ife, et al.
Publicado: (2021)

Author Directory
Publicado: (2013)

Author Index
Publicado: (2013)

Author Correction: Glucose and fatty acid metabolism involved in the protective effect of metformin against ulipristal-induced endometrial changes in rats
por: Hamza, Marwa S., et al.
Publicado: (2021)

Author Correction: Dynamic changes of muscle insulin sensitivity after metabolic surgery
por: Gancheva, Sofiya, et al.
Publicado: (2022)

Glucose Metabolism in Children With Growth Hormone Deficiency
por: Ciresi, Alessandro, et al.
Publicado: (2018)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sl79ncf0g49o6vuja0pf5j1j98